Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ProMIS Neurosciences Inc. (PMN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PMN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.95% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.11M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 3 | Beta -0.17 | 52 Weeks Range 0.38 - 1.59 | Updated Date 10/17/2025 |
52 Weeks Range 0.38 - 1.59 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -281.41% | Return on Equity (TTM) -19.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19712631 | Price to Sales(TTM) 5168.19 |
Enterprise Value 19712631 | Price to Sales(TTM) 5168.19 | ||
Enterprise Value to Revenue 3868.08 | Enterprise Value to EBITDA -1.74 | Shares Outstanding 53811110 | Shares Floating 32333471 |
Shares Outstanding 53811110 | Shares Floating 32333471 | ||
Percent Insiders 34.67 | Percent Institutions 24.54 |
Upturn AI SWOT
ProMIS Neurosciences Inc.
Company Overview
History and Background
ProMIS Neurosciences Inc. is a biotechnology company focused on developing precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. Founded to address the need for more effective treatments targeting the root causes of these diseases, ProMIS utilizes its proprietary discovery platform to identify and develop novel antibody therapeutics.
Core Business Areas
- Antibody Therapeutics Development: ProMIS focuses on discovering and developing antibody therapeutics that selectively target toxic protein aggregates implicated in neurodegenerative diseases. The platform identifies unique epitopes on misfolded proteins, allowing for highly specific antibody design.
Leadership and Structure
ProMIS Neurosciences Inc. is led by a management team with expertise in drug development and neuroscience. The organizational structure is designed to support research and development activities, including target validation, antibody engineering, and preclinical testing.
Top Products and Market Share
Key Offerings
- PMN310: PMN310 is ProMIS's lead antibody candidate being developed for Alzheimer's disease. It is designed to selectively target toxic amyloid-beta oligomers. The company is advancing PMN310 through preclinical and clinical development. Competitors developing similar therapies include Biogen (lecanemab), Eli Lilly (donanemab), and Roche (gantenerumab).
Market Dynamics
Industry Overview
The industry is characterized by high unmet medical need, significant investment in research and development, and increasing regulatory support for novel therapies targeting neurodegenerative diseases. There is a high attrition rate in clinical trials, reflecting the complexity of these diseases.
Positioning
ProMIS is positioned as a precision medicine company focused on developing highly selective antibody therapeutics. Its competitive advantage lies in its proprietary discovery platform, which allows for the identification of unique epitopes on misfolded proteins.
Total Addressable Market (TAM)
The total addressable market for Alzheimer's disease therapies is substantial, estimated to be worth tens of billions of dollars annually. ProMIS aims to capture a significant portion of this market with its targeted antibody approach.
Upturn SWOT Analysis
Strengths
- Proprietary discovery platform for identifying toxic protein aggregates
- Highly selective antibody design
- Focus on precision medicine
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early stage clinical development
- High attrition rate in clinical trials for neurodegenerative diseases
- Reliance on external funding
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results for PMN310
- Expansion of the discovery platform to other neurodegenerative diseases
- Growing demand for effective Alzheimer's disease therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- RO
Competitive Landscape
ProMIS faces intense competition from established pharmaceutical companies with greater financial resources and more advanced clinical programs. ProMISu2019s competitive advantage lies in its discovery platform, which may lead to more effective and safer therapies. However, it's a risk to only have one product.
Growth Trajectory and Initiatives
Historical Growth: ProMIS's historical growth has been driven by advancements in its discovery platform and preclinical development of its antibody candidates. The company's growth trajectory is dependent on successful clinical trial outcomes and partnerships.
Future Projections: Future growth projections are highly uncertain and dependent on the successful development and commercialization of PMN310 and other antibody candidates. Analyst estimates vary widely, reflecting the high risk and high reward nature of biotechnology investments.
Recent Initiatives: Recent initiatives include advancing PMN310 through clinical trials, expanding the discovery platform to other neurodegenerative diseases, and seeking partnerships with larger pharmaceutical companies.
Summary
ProMIS Neurosciences is a high-risk, high-reward biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases. Its strength lies in its proprietary discovery platform, but it faces challenges due to limited financial resources and intense competition. Positive clinical trial results for PMN310 would be a major catalyst for growth, while clinical failures would significantly impact the company's outlook. The company needs to look into partnering with other large companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProMIS Neurosciences Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2007-07-17 | CEO, President, Compliance Officer & Director Mr. Neil K. Warma M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.